According to an editorial, composite outcomes in trials work well when the rate of death is not affected by the study intervention or when rates of death move in the same direction as the nonfatal component or components of interest. The commentator notes that interpretation of these neonatal composite outcomes, however, is more problematic when treatment effects move in opposite directions, as in this trial, and uncertainty thus remains with respect to the use of early inhaled glucocorticoids to prevent bronchopulmonary dysplasia in extremely preterm infants.